[
  {
    "ts": null,
    "headline": "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint.i Participants who rece",
    "url": "https://finnhub.io/api/news?id=b2e45286e7e2271ea0b740bbe70a8488874db0e10da73e21bd5ed45385033abb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743359400,
      "headline": "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels",
      "id": 133622625,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint.i Participants who rece",
      "url": "https://finnhub.io/api/news?id=b2e45286e7e2271ea0b740bbe70a8488874db0e10da73e21bd5ed45385033abb"
    }
  },
  {
    "ts": null,
    "headline": "1 Growth Stock With Major Catalysts on the Way to Buy and Hold",
    "summary": "After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year.  Its financial results, though solid compared to similarly sized peers, were not always up to investors' high standards for the market-leading drugmaker.  It's no secret that Eli Lilly is one of the leaders in the market for weight management drugs.",
    "url": "https://finnhub.io/api/news?id=ac48d667a17123b42f129397279f0040243a910c0bba09b22c94a25db65d5b8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743318780,
      "headline": "1 Growth Stock With Major Catalysts on the Way to Buy and Hold",
      "id": 133597463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year.  Its financial results, though solid compared to similarly sized peers, were not always up to investors' high standards for the market-leading drugmaker.  It's no secret that Eli Lilly is one of the leaders in the market for weight management drugs.",
      "url": "https://finnhub.io/api/news?id=ac48d667a17123b42f129397279f0040243a910c0bba09b22c94a25db65d5b8b"
    }
  },
  {
    "ts": null,
    "headline": "abrdn World Healthcare Fund Q4 2024 Commentary",
    "summary": "abrdn World Healthcare Fund Q4 2024 Commentary",
    "url": "https://finnhub.io/api/news?id=e424a624d3ccbbcf72e63c708c1d194dad5e933e215b0ca6eba6b0c429aa41cf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743318600,
      "headline": "abrdn World Healthcare Fund Q4 2024 Commentary",
      "id": 133605721,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e424a624d3ccbbcf72e63c708c1d194dad5e933e215b0ca6eba6b0c429aa41cf"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
    "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
    "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743310800,
      "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
      "id": 133598030,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453972690/image_1453972690.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
      "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Healthcare Opportunities Fund Q4 2024 Commentary",
    "summary": "The equity portion of the Abrdn Healthcare Opportunities Fund fell (gross) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=a5933eccf4e0954a3d6ef92d4832f42825c89b4de8dd9bba832d8a1bb2aa2d23",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743305100,
      "headline": "abrdn Healthcare Opportunities Fund Q4 2024 Commentary",
      "id": 133592692,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1409312575/image_1409312575.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The equity portion of the Abrdn Healthcare Opportunities Fund fell (gross) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=a5933eccf4e0954a3d6ef92d4832f42825c89b4de8dd9bba832d8a1bb2aa2d23"
    }
  }
]